Binge drinking episode causes acute, specific alterations in systemic and hepatic inflammation-related markers
- PMID: 37592403
- DOI: 10.1111/liv.15692
Binge drinking episode causes acute, specific alterations in systemic and hepatic inflammation-related markers
Abstract
Background: Frequent binge drinking is a known contributor to alcohol-related harm, but its impact on systemic and hepatic inflammation is not fully understood. We hypothesize that changes in immune markers play a central role in adverse effects of acute alcohol intake, especially in patients with early liver disease.
Aim: To investigate the effects of acute alcohol intoxication on inflammation-related markers in hepatic and systemic venous plasma in people with alcohol-related liver disease (ArLD), non-alcoholic fatty liver disease (NAFLD) and healthy controls.
Methods: Thirty-eight participants (13 with ArLD, 15 with NAFLD and 10 healthy controls) received 2.5 mL of 40% ethanol per kg body weight via a nasogastric tube. Seventy-two inflammation-related markers were quantified in plasma from hepatic and systemic venous blood, at baseline, 60 and 180 min after intervention.
Results: Alcohol intervention altered the levels of 31 of 72 and 14 of 72 markers in the systemic and hepatic circulation. All changes observed in the hepatic circulation were also identified in the systemic circulation after 180 min. Only FGF21 and IL6 were increased after alcohol intervention, while the remaining 29 markers decreased. Differences in response to acute alcohol between the groups were observed for 8 markers, and FGF21 response was blunted in individuals with steatosis.
Conclusion: Acute alcohol intoxication induced changes in multiple inflammation-related markers, implicated in alcohol metabolism and hepatocellular damage. Differences identified between marker response to binge drinking in ArLD, NAFLD and healthy controls may provide important clues to disease mechanisms and potential targets for treatment.
Clinical trial number: NCT03018990.
Keywords: alcohol; inflammation; liver disease; proteomics.
© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593-608.
-
- Sheron N. Alcohol and liver disease in Europe - simple measures have the potential to prevent tens of thousands of premature deaths. J Hepatol. 2016;64:957-967.
-
- Teli MR, Day CP, James OFW, Burt AD, Bennett MK. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995;346:987-990.
-
- Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology. 2017;65:2090-2099.
-
- Åberg F, Puukka P, Salomaa V, et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease. Clin Gastroenterol Hepatol. 2020;18:995-997.e2.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
